rejuvant life tabs

Building a longevity biotech from scratch

Latest articles

A single source for longevity nutrition data

Edamam co-founder talks bringing nutrition into the digital world and seeking funding for expansion in food as medicine. When it comes to food nutrition data,...

The Sheekey Science Show – Senotherapeutics

Senotherapeutics are therapeutics strategies that target cellular senescence. They can work by killing senescent cells (senolytics), inhibiting the proinflammatory secretory phenotype of senescent cells (senomorphics)...

Michael Greve commits €300m for rejuvenation start-ups

The founder of Forever Healthy has committed €300 million to advance rejuvenation biotech start-ups – plus exclusive insights from Michael Greve. Michael Greve, founder of...

Capsida Biotherapeutics emerges from stealth with $140m

Versant Ventures and Westlake Village BioPartners launch next-generation gene therapy company with $50m series A; AbbVie collaboration provides $90m for gene therapies for CNS...

Most read

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...
Supplement report

Editor's picks

A single source for longevity nutrition data

Edamam co-founder talks bringing nutrition into the digital world and seeking funding for expansion in food as medicine. When it comes to food nutrition data,...

The Sheekey Science Show – Senotherapeutics

Senotherapeutics are therapeutics strategies that target cellular senescence. They can work by killing senescent cells (senolytics), inhibiting the proinflammatory secretory phenotype of senescent cells (senomorphics)...

Michael Greve commits €300m for rejuvenation start-ups

The founder of Forever Healthy has committed €300 million to advance rejuvenation biotech start-ups – plus exclusive insights from Michael Greve. Michael Greve, founder of...
Rejuvant

Alchemab exec talks company creation and how antibody therapeutics may play a role in longevity biotech.

Last week, we covered Alchemab Therapeutics’ $82 million Series A funding round for the development of its platform for identifying disease-modifying antibody therapeutics. In addition to cancers and neurodegeneration, the company told us that also aims to discover “whether there is an immune component, and specifically a B-cell component to longevity.”

Longevity.Technology: Alchemab is one of the companies to emerge from SV Health Investors’ biotech company creation fund. Former SV Principal, Dr Olivia Cavlan, is now head of business and operations at Alchemab, and we caught up with her to find out more about the company’s origins.

Alchemab’s origins are a little different from most longevity biotech companies, with SV coming up with a theoretical concept for a company and then exploring the best way to build it.

“It’s what we call unbiased drug discovery, because we’re using the body to tell us what targets to go after, as opposed to picking those targets, and then trying to understand what they do,” says Cavlan.

From concept to company

The theory behind Alchemab’s formation was initially developed in 2019 by SV Managing Partner and biotech entrepreneur, Houman Ashrafian.

“The concept was essentially, what keeps you well, and what is the role of B-cells in that?” says Cavlan, pointing out that there is a growing body of evidence showing the protective components of B-cells (antibodies) immune response in both cancer and neurodegeneration. “And then the question was, what are the technologies we’re going to use to un-tease that?”

Finding the answers to these questions is part of SV’s “incubation phase” when creating a company, and the company assembled a team of scientific founders from top universities with the knowledge needed to answer them.

Understanding antibodies

The first component was understanding the antibody repertoires of individuals who are resistant to or recovered from disease. The company’s next challenge was to identify similar antibodies across multiple individuals.

Alchemab
Alchemab’s platform approach to developing therapeutic antobodies.

“Getting the same antibody across different individuals is very rare,” says Cavlan. “But if you found the same one that was uniquely in the resilient group, that’s not in the normal disease group and not in a healthy control group, then you can say the resilient antibody could have some kind of role in the disease.”

Elevant

Alchemab uses deep learning and bioinformatics identify those convergent B-cell repertoires, before moving on to the third challenge of antibody deconvolution.

“For this we use something called PhIP-Seq (phage immunoprecipitation sequencing), which comes out of Johns Hopkins University,” explains Cavlan. “It allows you to put these antibodies onto a proteomic display and see if they bind to the same antigen.”

The company then moved quickly to build out its management team and establish relationships with organisations including academic institutions, biobanks and other industry partners. In addition to moving forward with its cancer and neurodegeneration efforts, Alchemab has moved quickly to sequence antibody repertoires of COVID-19 patients to identify convergent signatures, as well as engaging with the UK’s Medicines Discovery Catapult on Huntingdon’s disease.

Antibodies and longevity

And, Cavlan confirms, learning more about B-cells’ role in healthy aging is also a key factor in the company’s activities.

“As we were building out the hypothesis on what diseases to go after, a part of that considered healthy aged individuals – what about the supercentenarians who are cognitively outstanding? It would be silly to develop a platform company that is very applicable to cancer and neurodegeneration, and not to look at groups like healthy aged supercentenarians, and try to understand how they fit against these other diseases.”

The next steps for Alchemab are to use the funding to build out the discovery platform, starting with bringing in as many samples as possible.

“The more samples you get in house, the more confidence you’re going to have about what you deconvolute,” says Cavlan. “And so we’d love to hear from any groups of patients out there who have a resilient phenotype, and who would be willing to provide their samples for us to have a look at and see if there is anything going on from a B-cell perspective.”

Elevant

“And then once we’ve found convergent antibodies, the question is, what are they binding to? This funding will also enable us to build out that capability, which will then help us advance our current programmes further to clinic.”

Images courtesy of Alchemab

Comment on this article

Danny Sullivan
Contributing Editor Danny has worked in technology communications for more than 15 years, spanning Europe and North America. From bionics and lasers to software and pharmaceuticals – and everything in between – he’s covered it all. Danny has wide experience of technology publishing and technical writing and has specific interest in the transfer from idea to market.
Rejuvant

Most popular

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

Is nicotinamide riboside a safe and effective way to combat aging?

ChromaDex executive highlights the importance of clinical studies to prove the benefits of NAD+ boosting compound. ChromaDex is the company behind the popular healthy aging...
Supplement report

Related articles

Michael Greve commits €300m for rejuvenation start-ups

The founder of Forever Healthy has committed €300 million to advance rejuvenation biotech start-ups – plus exclusive insights from Michael Greve. Michael Greve, founder of...

Capsida Biotherapeutics emerges from stealth with $140m

Versant Ventures and Westlake Village BioPartners launch next-generation gene therapy company with $50m series A; AbbVie collaboration provides $90m for gene therapies for CNS...

FOXO exclusively licenses epigenetic clocks from UCLA

FOXO Technologies' exclusive licence of epigenetic clocks PhenoAge and GrimAge from UCLA could be an insurance game-changer. FOXO Technologies Inc has announced the licence of...

Longevity investment: small sums behind big ideas

Sonia Arrison talks about her journey to becoming an early stage investor and what longevity means to her. While longevity is now seeing increasing interest...

ChromaDex and H&H announce Niagen supply agreement

H&H Group expands Swisse healthy aging product line into growing NAD+ space with Niagen from ChromaDex. Los Angeles-based ChromaDex has announced it entered into a strategic...
Supps report ad middle